View Past PerformancePharma-Bio Serv 대차대조표 건전성재무 건전성 기준 점검 6/6Pharma-Bio Serv 의 총 주주 지분은 $10.5M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $11.5M 및 $1.0M 입니다.핵심 정보0%부채/자본 비율US$0부채이자보상배율n/a현금US$8.47m자본US$10.45m총부채US$1.05m총자산US$11.50m최근 재무 건전성 업데이트공시 • Feb 02Pharma-Bio Serv, Inc. announced delayed annual 10-K filingOn 02/01/2021, Pharma-Bio Serv, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.모든 업데이트 보기Recent updates공시 • Apr 17Pharma-Bio Serv, Inc., Annual General Meeting, May 15, 2026Pharma-Bio Serv, Inc., Annual General Meeting, May 15, 2026. Location: at the law offices of akerman llp, at 1875 nw corporate boulevard, suite 275, fl 33431, boca raton United States공시 • Apr 22Pharma-Bio Serv, Inc., Annual General Meeting, May 15, 2025Pharma-Bio Serv, Inc., Annual General Meeting, May 15, 2025. Location: at the lawoffices of akerman llp, at 201 east las olas boulevard, suite 1800, florida 33301, lauderdale, United States공시 • Jan 31Pharma-Bio Serv, Inc. Approves Special Dividend, Payable on or About March 20, 2025Pharma-Bio Serv, Inc. announced that the Board of Directors approved a Special Dividend of $0.075 per share for shareholders. The Special Dividend will be payable on or about March 20, 2025 to shareholders of record at the close of business on February 28, 2025.공시 • Apr 09Pharma-Bio Serv, Inc., Annual General Meeting, May 02, 2024Pharma-Bio Serv, Inc., Annual General Meeting, May 02, 2024, at 10:00 Eastern Daylight. Location: the law offices of Akerman LLP at 201 East Las Olas Boulevard, Suite 1800, Ft. Lauderdale Florida United States Agenda: To consider the election of two (2) directors as Class II directors to serve for a term until the 2027 Annual Meeting of Stockholders or until his successor is duly elected and qualified; to consider the ratification of the selection of Crowe PR PSC as the Company’s independent certified public accountants for the fiscal year ending October 31, 2024; to consider the transaction of such other and further business as may properly come before the meeting or any, adjournments or postponements of the meeting.공시 • Jan 31Pharma-Bio Serv, Inc. Approves Special Dividend, Payable on or About February 15, 2024Pharma-Bio Serv, Inc. announced that the Board of Directors approved a Special Dividend of $0.075 per share payable on or about February 15, 2024, to shareholders of record at the close of business on January 30, 2024.공시 • Dec 21Pharma-Bio Serv, Inc. Approves Special Dividend, Payable on or About February 15, 2024Pharma-Bio Serv, Inc. announced that the Board of Directors approved a special dividend of $0.075 per share for Shareholders. The special dividend will be payable on or about February 15, 2024 to shareholders of record at the close of business on January 30, 2024.공시 • May 28Pharma-Bio Serv, Inc., Annual General Meeting, Jun 23, 2022Pharma-Bio Serv, Inc., Annual General Meeting, Jun 23, 2022, at 10:00 US Eastern Standard Time. Location: the law offices of Akerman LLP at 201 East Las Olas Blvd., Suite 1800, Fort Lauderdale, Florida 33301 Florida United States Agenda: To elect of one (1) director as Class III director to serve for a term until the 2025 Annual Meeting of Stockholders or until his successor is duly elected and qualified; to consider the ratification of the selection of Crowe PR PSC as the Company’s independent certified public accountants for the fiscal year ending October 31, 2022; A non-binding advisory vote on the compensation of the named executive officers of the Company (“Say on Pay”); and to consider other matters if any.공시 • Feb 15Pharma-Bio Serv, Inc. Approves Special Dividend, Payable on or About March 15, 2022Pharma-Bio Serv, Inc.'s Board of Directors approved a special dividend of $0.075 per share to shareholders. The dividend is payable on or about March 15, 2022 to shareholders of record at the close of business on February 25, 2022.공시 • May 08U.S. District Court for the District of Puerto Rico Enters Judgment Dismissing with Prejudice All Claims Brought Against Pharma-Bio Serv, Inc. and Pharma-Bio Serv PR, IncOn April 30, 2021, the U.S. District Court for the District of Puerto Rico entered judgment dismissing with prejudice all claims brought against Pharma-Bio Serv, Inc. (the Company) and the company's wholly-owned subsidiary, Pharma-Bio Serv PR, Inc., (Pharma PR) as previously disclosed in the Company's Quarterly Report on Form 10-Q for the period ended January 31, 2021, which was filed on March 17, 2021. In connection with the dismissal, plaintiff agreed not to file separate claims against the officers or directors of the Company or Pharma PR.공시 • Feb 02Pharma-Bio Serv, Inc. announced delayed annual 10-K filingOn 02/01/2021, Pharma-Bio Serv, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Jan 12Pharma-Bio Serv, Inc. Announces the Resignation of Elizabeth Plaza as DirectorOn January 7, 2021, Elizabeth Plaza resigned as a director of Pharma-Bio Serv, Inc., effective immediately.공시 • Jan 06Pharma-Bio Serv, Inc. Appoints Kirk Michel as Chairman of the Board of DirectorsPharma-Bio Serv, Inc. announced the appointment of Kirk Michel as Chairman of the Board of Directors, effective January 4, 2021. Mr. Michel has served as a director of the company since January 2006.재무 상태 분석단기부채: PBSV 의 단기 자산 ( $11.3M )이 단기 부채( $1.0M ).장기 부채: PBSV에는 장기 부채가 없습니다.부채/자본 비율 추이 및 분석부채 수준: PBSV 부채가 없습니다.부채 감소: PBSV는 5년 전 부채 대비 자본 비율이 9%였으나 현재 부채가 없습니다.부채 범위: PBSV 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.이자 보장: PBSV 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.대차대조표건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/24 20:36종가2026/06/15 00:00수익2026/04/30연간 수익2025/10/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pharma-Bio Serv, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jack WallaceSidoti & Company, LLCBradley SorensenZacks Small-Cap ResearchElizabeth SenkoZacks Small-Cap Research
공시 • Feb 02Pharma-Bio Serv, Inc. announced delayed annual 10-K filingOn 02/01/2021, Pharma-Bio Serv, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Apr 17Pharma-Bio Serv, Inc., Annual General Meeting, May 15, 2026Pharma-Bio Serv, Inc., Annual General Meeting, May 15, 2026. Location: at the law offices of akerman llp, at 1875 nw corporate boulevard, suite 275, fl 33431, boca raton United States
공시 • Apr 22Pharma-Bio Serv, Inc., Annual General Meeting, May 15, 2025Pharma-Bio Serv, Inc., Annual General Meeting, May 15, 2025. Location: at the lawoffices of akerman llp, at 201 east las olas boulevard, suite 1800, florida 33301, lauderdale, United States
공시 • Jan 31Pharma-Bio Serv, Inc. Approves Special Dividend, Payable on or About March 20, 2025Pharma-Bio Serv, Inc. announced that the Board of Directors approved a Special Dividend of $0.075 per share for shareholders. The Special Dividend will be payable on or about March 20, 2025 to shareholders of record at the close of business on February 28, 2025.
공시 • Apr 09Pharma-Bio Serv, Inc., Annual General Meeting, May 02, 2024Pharma-Bio Serv, Inc., Annual General Meeting, May 02, 2024, at 10:00 Eastern Daylight. Location: the law offices of Akerman LLP at 201 East Las Olas Boulevard, Suite 1800, Ft. Lauderdale Florida United States Agenda: To consider the election of two (2) directors as Class II directors to serve for a term until the 2027 Annual Meeting of Stockholders or until his successor is duly elected and qualified; to consider the ratification of the selection of Crowe PR PSC as the Company’s independent certified public accountants for the fiscal year ending October 31, 2024; to consider the transaction of such other and further business as may properly come before the meeting or any, adjournments or postponements of the meeting.
공시 • Jan 31Pharma-Bio Serv, Inc. Approves Special Dividend, Payable on or About February 15, 2024Pharma-Bio Serv, Inc. announced that the Board of Directors approved a Special Dividend of $0.075 per share payable on or about February 15, 2024, to shareholders of record at the close of business on January 30, 2024.
공시 • Dec 21Pharma-Bio Serv, Inc. Approves Special Dividend, Payable on or About February 15, 2024Pharma-Bio Serv, Inc. announced that the Board of Directors approved a special dividend of $0.075 per share for Shareholders. The special dividend will be payable on or about February 15, 2024 to shareholders of record at the close of business on January 30, 2024.
공시 • May 28Pharma-Bio Serv, Inc., Annual General Meeting, Jun 23, 2022Pharma-Bio Serv, Inc., Annual General Meeting, Jun 23, 2022, at 10:00 US Eastern Standard Time. Location: the law offices of Akerman LLP at 201 East Las Olas Blvd., Suite 1800, Fort Lauderdale, Florida 33301 Florida United States Agenda: To elect of one (1) director as Class III director to serve for a term until the 2025 Annual Meeting of Stockholders or until his successor is duly elected and qualified; to consider the ratification of the selection of Crowe PR PSC as the Company’s independent certified public accountants for the fiscal year ending October 31, 2022; A non-binding advisory vote on the compensation of the named executive officers of the Company (“Say on Pay”); and to consider other matters if any.
공시 • Feb 15Pharma-Bio Serv, Inc. Approves Special Dividend, Payable on or About March 15, 2022Pharma-Bio Serv, Inc.'s Board of Directors approved a special dividend of $0.075 per share to shareholders. The dividend is payable on or about March 15, 2022 to shareholders of record at the close of business on February 25, 2022.
공시 • May 08U.S. District Court for the District of Puerto Rico Enters Judgment Dismissing with Prejudice All Claims Brought Against Pharma-Bio Serv, Inc. and Pharma-Bio Serv PR, IncOn April 30, 2021, the U.S. District Court for the District of Puerto Rico entered judgment dismissing with prejudice all claims brought against Pharma-Bio Serv, Inc. (the Company) and the company's wholly-owned subsidiary, Pharma-Bio Serv PR, Inc., (Pharma PR) as previously disclosed in the Company's Quarterly Report on Form 10-Q for the period ended January 31, 2021, which was filed on March 17, 2021. In connection with the dismissal, plaintiff agreed not to file separate claims against the officers or directors of the Company or Pharma PR.
공시 • Feb 02Pharma-Bio Serv, Inc. announced delayed annual 10-K filingOn 02/01/2021, Pharma-Bio Serv, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Jan 12Pharma-Bio Serv, Inc. Announces the Resignation of Elizabeth Plaza as DirectorOn January 7, 2021, Elizabeth Plaza resigned as a director of Pharma-Bio Serv, Inc., effective immediately.
공시 • Jan 06Pharma-Bio Serv, Inc. Appoints Kirk Michel as Chairman of the Board of DirectorsPharma-Bio Serv, Inc. announced the appointment of Kirk Michel as Chairman of the Board of Directors, effective January 4, 2021. Mr. Michel has served as a director of the company since January 2006.